CADTH Rapid Response Report: Clinical evidence for Suboxone® (buprenorphine/naloxone) for short-term detoxification

by pgh on September 14, 2011

Source: Canadian Agency for Drugs and Technologies in Health (CADTH)
Area: News
This Rapid Response Report from the Canadian Agency for Drugs and Technologies in Health (CADTH) discusses the available evidence regarding the comparative clinical efficacy and safety of short term (<4 weeks) use of Suboxone® (buprenorphine/naloxone) compared with other opioid detoxification agents such as buprenorphine alone, methadone, and clonidine, and placebo.
The results of their limited literature search are described and summarised in the report (see link below); the main conclusions drawn were as follows:
. The evidence comparing the clinical effectiveness of short term Suboxone® detoxification with other alternative medications in the treatment of patients with opioid…

MedWorm Sponsor Message: Find out how you can get your message posted here and on over 100,000 other medical web pages in just a couple of days, plus support MedWorm at the same time.

Previous post:

Next post: